Oppenheimer raised the firm’s price target on Astria Therapeutics (ATXS) to $28 from $26 and keeps an Outperform rating on the shares.

Oppenheimer upgraded PMV Pharmaceuticals (PMVP) to Outperform from Perform with a $6 price target Published first on TheFly – the ...

The Atomic Rocketeer, a new feature documentary directed by Larry L. Sheffield and Trent J DiGiulio, tells the story of […] ...

The grant will support Perspectum’s research into the development of a novel biomarker for primary sclerosing cholangitis ...

Mark Gould and his team had brought in sales of £7m and had more than 50,000 customers when the 36-year-old’s flat in ...

Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsEdward Berg - Senior Vice President and ...

Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Dianthus Therapeutics in a research ...

Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Terns Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Arce forecasts that the ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

TransMedics (NASDAQ: TMDX) stock soared by 123% -- but the good times didn't last. A third-quarter earnings miss sent shares ...

Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc ...

Q3 2024 Earnings Call Transcript November 7, 2024 MannKind Corporation beats earnings expectations. Reported EPS is $0.05, ...